Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?

Health Economics

Volumn 5, Issue 3, 1996, Pages 217-226

  Coast, Joanna ^a   Smith, Richard D ^a   Millar, Michael R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antimicrobial resistance costs; Economic evaluation; Externality

Indexed keywords

ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HEALTH SERVICES RESEARCH; HUMAN; MICROBIOLOGY; REVIEW; TIME; UNITED STATES;

BIAS (EPIDEMIOLOGY); COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG RESISTANCE, MICROBIAL; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; TIME FACTORS; UNITED STATES;

EID: 0030136395     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S     Document Type: Review

References (29)

1. Kubin, C. M. Resistance to antimicrobial drugs - a worldwide calamity. Annals of Internal Medicine, 1993; 118: 557-561.
2. Murray, B. E. Can antibiotic resistance be controlled? New England Journal of Medicine, 1994; 330: 1229-1230.
3. Levy, J. Antibiotic resistance in Europe and the current use of antibiotics in severe pediatric infections. Scandinavian Journal of Infectious Diseases, 1990; 73: 23-29.
4. Tomasz, A. Multiple-antibiotic resistant pathogenic bacteria. A report on the Rockefeller University workshop. New England Journal of Medicine, 1994; 330: 1247-1251.
5. Williams, J. D. Antibiotic policy. Scandinavian Journal of Infectious Diseases, 1986; 49: 175-181.
6. Horton, R. The infected metropolis. Lancet, 1996; 347: 134-135.
7. Neu, H. C. The crisis in antibiotic resistance. Science, 1992; 257: 1064-1073.
8. American Society for Microbiology. Report of the ASM task force on antibiotic resistance. Antimicrobial Agents and Chemotherapy, 1995; Supplement: 1-23.
9. Cox, R. A., Conquest, C., Mallaghan, C. and Marples, R. R. A major outbreak of methicillin-resistant Staphylococcus aureus caused be a new phage-type (EMRSA-16). Journal of Hospital Infection, 1995; 29: 87-106.
10. Neu, H. C. Antimicrobial chemotherapy, 1934-1994. Antimicrobial Infectious Diseases Newsletter, 1994; 13: 1-8.
11. Drummond, M. F., Stoddart, G. L. and Torrance, G. W. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
12. Wiggins, R. J. Antibiotic resistance: the information gap. Hospital Update, 1995; April: 155.
13. Mishan, E. J. Cost-benefit analysis. An informal introduction, 4th edition. London: Unwin Hyman, 1988.
14. Layard, R. and Glaister, S. Cost benefit analysis. Cambridge: Cambridge University Press, 1994.
15. Cooke, J. and Tillotson, G. Use of cost minimization analysis for the rational selection and use of oral ciprofloxacin. Review of Contemporary Pharmacotherapy, 1992; 3: 167-172.
16. Pizzo, P. A., Hathom, J. W., Hiemenz, J., Browne, M. and Commers, J. A randomised trial comparing ceftazidine alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine, 1986; 315: 552-528.
17. Gladen, H. E. Computer modelling antibiotic therapy costs. Impact of therapeutic range. Drugs, 1988; 35 (Suppl. 2): 208-213.
18. Mohle-Boetani, J. C., Schuchat, A., Plikaytis, B. D., Smith, J. D. and Broome, C. V. Comparison of prevention strategies for neonatal group B streptococcal infection. A population based economic analysis. Journal of the American Medical Association, 1993; 270: 1442-1448.
19. MacDonald, T. The economic evaluation of antibiotic therapy: relevance to urinary tract infection. Journal of Antimicrobial Chemotherapy, 1994; 33 (Suppl.): A137-145.
20. Holmberg, S. D., Solomon, S. L. and Blake, P. A. Health and economic impacts of antimicrobial resistance. Review of Infectious Diseases, 1987; 9: 1065-1078.
21. Gruneberg, R. The Alexander project - the first two years. Canadian Journal of Infectious Diseases, 1995; 6 (Suppl. C): 226C.
22. Krahn, M. and Gafni, A. Discounting in the economics evaluation of health care interventions. Medical Care, 1993; 31: 403-418.
23. Sheldon, T. A. Discounting in health care decisionmaking: time for a change? Journal of Public Health Medicine, 1992; 14: 250-256.
24. Broome, J. Discounting the future. Philosophy and public affairs, 1994; 23: 128-156.
25. Sugden, R. and Williams, A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press, 1978.
26. Shlaes, D., Levy, S. and Archer, G. Antimicrobial resistance: new directions. ASM News, 1991; 57: 455-458.
27. Davey, P. G., Malek, M. and Parker, S. E. Pharmacoeconomics of antibacterial treatment. PharmacoEconomics, 1992; 1: 409-437.
28. Boadway, R. W. and Bruce, N. Welfare economics. Oxford: Blackwell, 1993.
29. Simmons, H. E. and Stolley, P. D. This is medical progress? Trends and consequences of antibiotic use in the United States. Journal of the American Medical Association, 1974; 227: 1023-1028.